About Karyopharm
Karyopharm is a company based in Natick (United States) founded in 2008 by Sharon Shacham. Karyopharm has raised $98.4 million across 12 funding rounds from investors including New Leaf Venture Partners, Marshall Wace and Citadel. The company has 279 employees. Karyopharm offers products and services including SINE Technology and XPO1 Inhibition. Karyopharm operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Natick, United States
- Employees 279
- Founders Sharon Shacham
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website karyopharm.com
- Social LinkedIn X
- Legal Name Karyopharm Therapeutics Inc.
- Annual Revenue$146.07 M (USD)0.57as on Dec 31, 2025
- Net Profit-$196.04 M (USD)-156.52as on Dec 31, 2025
- EBITDA-$90.41 M (USD)24.09as on Dec 31, 2025
- Total Equity Funding$98.4M (USD)
in 12 rounds
- Latest Funding Round$30M (USD), Post-IPO
Mar 2026
- InvestorsNew Leaf Venture Partners
& 13 more
- Employee Count279
Products & Services of Karyopharm
Karyopharm offers a comprehensive portfolio of products and services, including SINE Technology and XPO1 Inhibition.
Inhibits nuclear export to target oncogenesis in various tumor types.
Technology addressing fundamental cancer cell mechanisms through research.
Funding Insights of Karyopharm
Karyopharm has successfully raised a total of $98.4M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $30 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $98.4M
- Total Rounds 12
- Last Round Post-IPO — $30M
- First Round $700,000
(Nov 2010)
- Investors Count 14
Latest 10 of 12 funding rounds of Karyopharm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $30M | Post-IPO | – | – | |
| Oct 2025 | $8.75M | Post-IPO | – | – | – |
| Dec 2022 | $165M | Post-IPO | – | – | |
| Oct 2018 | $22.5M | Post-IPO | – | – | – |
| Oct 2018 | $150M | Post-IPO | – | – | – |
| Apr 2016 | $2.2M | Grant | – | – | |
| Jul 2013 | $19M | Series B | – | Foresite Capital | |
| May 2013 | $48.2M | Series B | – | – | |
| May 2013 | $20.5M | Series A | – | – | – |
| Nov 2011 | $10M | Series A | – | – | – |
14 investors in total: 14 institutional.
Investors in Karyopharm
Karyopharm has secured backing from 14 investors, including institutional and venture fund investors. Prominent investors backing the company include New Leaf Venture Partners, Marshall Wace and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Long-short equity strategies are managed through specialized hedge funds. | 1997 | mwam.com | London, United Kingdom | |
Multiple sectors are invested in by this venture capital firm. | – | heightscapitalmanagement.tcc.mode | San Francisco, United States | |
Venture capital firm focused on multiple sectors | – | aviditypartners.tcc.mode | Dallas, United States | |
Multi-stage investment firm invests in healthcare and life sciences companies | – | foresitecapital.com | New York, United States | |
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Investments are made in life sciences firms across all stages. | – | delphiventures.com | Menlo Park, United States | |
Offers investment management and secure information access to clients and partners. | 2001 | adagecapital.com | Boston, United States | |
Global hedge fund managing long/short investments in health care and consumer sectors. | 2012 | armisticecapital.com | New York, United States | |
An investment management firm using long/short hedge fund strategies. | 2005 | healthcormanagement.com | New York, United States | |
Investment management services are offered by Rubric Capital. | – | rubriccapital.com | New York, United States |
Investor details for Karyopharm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Karyopharm
102 people are tracked at Karyopharm (65 in leadership, 7 in board & advisors, 30 in team); the tracked headcount is 279.
| Name | Role | Group |
|---|---|---|
Sharon Shacham | Co-Founder & President | Leadership |
Sohanya Cheng | Chief Commercial Officer & Head of Business Development | Leadership |
Girish Gudi | Vice President, Clinical Pharmacology | Leadership |
Trinayan Kashyap | Executive Director, Research And Translational Medicine | Leadership |
Jack Williams | Associate Director, Commercial Strategic Planning | Leadership |
Stuart Poulton | Chief Development Officer | Leadership |
Lori Macomber | EVP, CFO & Treasurer | Leadership |
Rong Fan | Associate Director, Clinical Pharmacology | Leadership |
Sree Anumolu | Vice President Business Development | Leadership |
Richard Paulson | President & CEO | Leadership |
James Accumanno | Chief Compliance Officer | Leadership |
Lisa DiPaolo | Chief Human Resources Officer | Leadership |
Reshma Rangwala | Chief Medical Officer & Head of Research | Leadership |
Sunitha Reddy Nalla | Vice President, Regulatory Affairs | Leadership |
Pietro Taverna | Vice President Research & Translational Medicine | Leadership |
Kenzie Huynh | Associate Director, Forecasting & Analytics | Leadership |
Guerry C. | Director, Global Medical And Scientific Affairs | Leadership |
Stephen Li | Senior Vice President, Regulatory Affairs | Leadership |
Andrea Bottkova | Senior Director, Procurement And Vendor Management At Karyopharm Therapeutics, Inc. | Leadership |
Steve Ferrari Ms | Vice President, External Partners & Communications | Leadership |
82 more people are available in the full profile.
Complete people profiles for Karyopharm
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Karyopharm
Karyopharm is a publicly listed company on the NASDAQ with ticker symbol KPTI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date06 Nov 2013
- Listed onNASDAQ: KPTI
- Listed entityKaryopharm Therapeutics Inc.
- Exchange sectorHealth technology
- ISINUS48576U2050
- Share price$0.60 (-6.98% on the day) · 2026-10-08
- Market capitalisation$13.6M
- EPS (diluted, trailing year)$-13.08
- Volume (last session)870,976
Financials of Karyopharm
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $146.1M | -$196.0M | -$90.4M |
| 2024 | $145.2M | -$76.4M | -$119.1M |
| 2023 | $146.0M | -$143.1M | -$129.0M |
| 2022 | $157.1M | -$165.3M | -$141.6M |
| 2021 | $209.8M | -$124.1M | -$90.1M |
Detailed financial statements for Karyopharm
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Karyopharm
4 dated milestones of Karyopharm across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Karyopharm is founded.
- Funding First funding round of $700K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $30.0M.
Competitors of Karyopharm
Karyopharm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| jazzpharma.com | 2003 | Dublin, Ireland | $265M | 2,800 | Novel biopharmaceutical medicines are developed for unmet medical needs. | |
| c4therapeutics.com | 2016 | Cambridge, United States | $223M | 121 | Small-molecule drugs for cancer treatment are developed via Degronimid platform. | |
| erasca.com | 2018 | San Diego, United States | $300M | 120 | Small molecule therapeutics for cancer treatment are developed. | |
| miragen.com | 2007 | Boulder, United States | $111.29M | 92 | MicroRNA-based therapeutics are developed for treating multiple diseases. | |
| mereobiopharma.com | 2015 | London, United Kingdom | $119M | 56 | Therapeutics for cancer and rare diseases are developed. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. |
Detailed competitors of Karyopharm
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Karyopharm
The website of Karyopharm (karyopharm.com) receives about 11.8K visits a month and ranks #3,094,808 among all websites worldwide, #4,092 in Biotechnology and Pharmaceuticals.
- Monthly visits11.8K
▲ 91.2% vs previous month
- Unique visitors2.9K
per month
- Global rank#3,094,808
among all websites
- Category rank#4,092
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.9
- Average visit1 min 02 sec
- DevicesDesktop 39% · Mobile 61%
Websites whose visitors overlap most with Karyopharm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| takedaoncology.com | 100% | 14.3K | #1,943,946 | View details | |
| alexion.com | 97% | 81.8K | #498,312 | View details | |
| servier.us | 95% | – | #2,050,491 | View details | |
| esperion.com | 90% | 16.4K | #1,899,294 | View details | |
| sorrentotherapeutics.com | 85% | 1.4K | #12,489,091 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 21 similar websites and full traffic analytics for Karyopharm
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 21 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Latest news on Karyopharm
Complete news archive for Karyopharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Karyopharm
10 companies that operate in the same segment as Karyopharm (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Karyopharm
Karyopharm was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Karyopharm is headquartered in Natick, United States. It is registered at Natick, Massachusetts, United States.
Karyopharm is a funded company, having raised a total of $98.4M across 12 funding rounds to date. The company's 1st funding round was a Series A of $10M, raised on Nov 2010.
Karyopharm has 279 employees.
Annual revenue of Karyopharm is $146.07M as on Dec 31, 2025.
Founded in 2008 and based in Natick, United States, small molecule drugs are developed by the company to address cancer and inflammatory diseases. These drugs target the nuclear pore complex to modulate key pathways involved in cell proliferation, inflammation, and nuclear-cytoplasmic protein transport. Operations focus on oncology and immunology sectors, with research centered on therapeutic interventions for unmet medical needs in these areas.
Karyopharm's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Karyopharm offers SINE Technology and XPO1 Inhibition.
Yes, Karyopharm is publicly traded on NASDAQ under the ticker symbol KPTI.
Karyopharm has 14 investors. Key investors include New Leaf Venture Partners, Marshall Wace, Citadel, Adage Capital Management, and Armistice Capital.
Karyopharm operates through Karyopharm Therapeutics Inc..